Median progression-free survival was 3.7 months, with 44.4% of patients being progression free at 6 months and 32.3% at 12 ...

Merck & Co. ($MRK) is betting on acquisitions to offset the looming revenue loss from the upcoming patent expiration of ...

Pembrolizumab, an anti-programmed death receptor-1 (PD-1) therapy, is currently approved under the brand name Keytruda ® for other gynecological cancers, including cervical cancer and endometrial ...

KEYTRUDA® (pembrolizumab) Plus Trodelvy® (sacituzumab govitecan-hziy) Reduced Risk of Disease Progression or Death by 35% Versus KEYTRUDA Plus Chemotherapy in First-Line PD-L1+ Metastatic Triple ...

Corina Dutcus, SVP, oncology global clinical development lead, Eisai, highlights how consistent survival data from the LEAP-002 study reaffirms lenvatinib’s value in first-line treatment of ...

Kazia Therapeutics (NASDAQ:KZIA) on Wednesday reported preliminary results from the first patient in its Phase 1b trial ...

CHICAGO -- Combining pembrolizumab (Keytruda) with sacituzumab govitecan (SG, Trodelvy) instead of chemotherapy as first-line treatment significantly reduced the risk of progression or death in ...

A phase 2 trial reveals that combining intratumoral BO-112 with pembrolizumab shows potential in treating anti–PD-1-resistant ...

The documents show that blockbuster cancer drugs like pembrolizumab (brand Keytruda), osimertinib (brand Tagrisso), and ...

Keytruda (pembrolizumab) is a prescription drug used to treat certain types of cancer in adults and some children. Keytruda isn’t known to interact with alcohol, other medications, or supplements.

Results from the Phase III KEYNOTE-689 trial show that adding perioperative Keytruda (pembrolizumab) to standard-of-care ...

Trodelvy® Plus Keytruda® Reduces Risk of Disease Progression or Death by 35% Versus Keytruda and Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer ...